![Deniz Can Guven(@DenizCanGuven1) 's Twitter Profileg](https://pbs.twimg.com/profile_images/1233827983816785920/sIKpuig3_200x200.jpg)
Deniz Can Guven
@DenizCanGuven1
Medical Oncologist
@myESMO Young Oncologist Committee Member
Editorial Board Member in @BMC Cancer, @PLOSONE, @thePeerJ, and @OfOncological
ID:1233823877911977985
29-02-2020 18:38:38
1,5K Tweet
1,6K Takipçi
1,3K Takip Edilen
![Deniz Can Guven(@DenizCanGuven1) 's Twitter Profile Photo Deniz Can Guven(@DenizCanGuven1) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/1233827983816785920/sIKpuig3_200x200.jpg)
![Deniz Can Guven(@DenizCanGuven1) 's Twitter Profile Photo Deniz Can Guven(@DenizCanGuven1) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/1233827983816785920/sIKpuig3_200x200.jpg)
Out in Science Magazine
Finding the missing link between☀️ and🦀
☑️Vit-D availability >⬆️ Immune activation and IO efficacy
☑️Regulation of GI microbiome by Vit-D availability>Role of B. fragilis 🦠🦠
🔎Paves the way for more IO and Vit-D studies (PROVIDENCE study)
Congrats
![OncoAlert(@OncoAlert) 's Twitter Profile Photo OncoAlert(@OncoAlert) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/1215669650333323266/z8agvcHA_200x200.jpg)
The OncoAlert🚨NEWSLETTER OUT
Covering May 2-8, 2024
REGISTER at OncoAlert360.com OR oncoalert.m-pages.com/nhMpwe/oncoale…
✅ The Lancet Commission on #ProstateCancer
✅DESTINY-PanTumor01
✅Osimertinib+Local tx for brain🧠mets in EGFRm #NSCLC 🫁
✅ASCENT in Triple Negative
![Erman Akkus(@Erman_Akkus) 's Twitter Profile Photo Erman Akkus(@Erman_Akkus) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/1451492444344922116/4k5Kxdfd_200x200.jpg)
📊GLP1 Agonists in T2DM and Risk of Prostate, Kidney, and Bladder Cancers
European Urology Oncology
🚨Bladder cancer
HR 1.47 (1.06–2.04), p = 0.02
compared to SGLT2 inhibitors
🚨Kidney cancer
HR 1.45 (1.13–1.86), p = 0.003
compared to metformin
🚨Prostate cancer
HR 1.32 (1.07–1.63), p
![Erman Akkus (@Erman_Akkus) on Twitter photo 2024-05-09 14:17:38 📊GLP1 Agonists in T2DM and Risk of Prostate, Kidney, and Bladder Cancers @EurUrolOncol 🚨Bladder cancer HR 1.47 (1.06–2.04), p = 0.02 compared to SGLT2 inhibitors 🚨Kidney cancer HR 1.45 (1.13–1.86), p = 0.003 compared to metformin 🚨Prostate cancer HR 1.32 (1.07–1.63), p 📊GLP1 Agonists in T2DM and Risk of Prostate, Kidney, and Bladder Cancers @EurUrolOncol 🚨Bladder cancer HR 1.47 (1.06–2.04), p = 0.02 compared to SGLT2 inhibitors 🚨Kidney cancer HR 1.45 (1.13–1.86), p = 0.003 compared to metformin 🚨Prostate cancer HR 1.32 (1.07–1.63), p](https://pbs.twimg.com/media/GNJKncCWgAAxm9l.jpg)
![Erman Akkus(@Erman_Akkus) 's Twitter Profile Photo Erman Akkus(@Erman_Akkus) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/1451492444344922116/4k5Kxdfd_200x200.jpg)
📢Esophageal SCC-Definitive CRT:
Capecitabin vs. XELOX vs. Cis-5FU
CRTCOESC trial
Journal of Clinical Oncology
✅2-year OS rates did not differ, capecitabine showed a lower incidence of grade ≥3 AEs
✅2 cycles of consolidation ChT provided better OS
➡️246 patients
➡️2 cycles of capecitabin or
![Erman Akkus (@Erman_Akkus) on Twitter photo 2024-05-08 11:42:29 📢Esophageal SCC-Definitive CRT: Capecitabin vs. XELOX vs. Cis-5FU CRTCOESC trial @JCO_ASCO ✅2-year OS rates did not differ, capecitabine showed a lower incidence of grade ≥3 AEs ✅2 cycles of consolidation ChT provided better OS ➡️246 patients ➡️2 cycles of capecitabin or 📢Esophageal SCC-Definitive CRT: Capecitabin vs. XELOX vs. Cis-5FU CRTCOESC trial @JCO_ASCO ✅2-year OS rates did not differ, capecitabine showed a lower incidence of grade ≥3 AEs ✅2 cycles of consolidation ChT provided better OS ➡️246 patients ➡️2 cycles of capecitabin or](https://pbs.twimg.com/media/GNDdgblXYAAB-5c.jpg)
![Eda Eylemer Mocan(@Eda_Eylmr_Mcn) 's Twitter Profile Photo Eda Eylemer Mocan(@Eda_Eylmr_Mcn) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/1581292599725408257/Jzgd0bg3_200x200.jpg)
🔈Are NECTIN4 amplifications genomic predictors of EV responses? ✅NECTIN4 amp 96% BOR
Nonamp 32% (<.001)
✅92% risk reduction for death (<.001)
⁉️Perhaps FISH might suffice without validation
ASCO ASCOPost ESMO - Eur. Oncology OncoAlert Yüksel Ürün Niklas Klümper Emre Yekedüz
![Eda Eylemer Mocan (@Eda_Eylmr_Mcn) on Twitter photo 2024-05-08 12:00:54 🔈Are NECTIN4 amplifications genomic predictors of EV responses? ✅NECTIN4 amp 96% BOR Nonamp 32% (<.001) ✅92% risk reduction for death (<.001) ⁉️Perhaps FISH might suffice without validation @ASCO @ASCOPost @myESMO @OncoAlert @DrYukselUrun @niklas_kluemper @yekeduz_emre 🔈Are NECTIN4 amplifications genomic predictors of EV responses? ✅NECTIN4 amp 96% BOR Nonamp 32% (<.001) ✅92% risk reduction for death (<.001) ⁉️Perhaps FISH might suffice without validation @ASCO @ASCOPost @myESMO @OncoAlert @DrYukselUrun @niklas_kluemper @yekeduz_emre](https://pbs.twimg.com/media/GNDhuiIWoAEWoE6.jpg)
![OncoAlert(@OncoAlert) 's Twitter Profile Photo OncoAlert(@OncoAlert) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/1215669650333323266/z8agvcHA_200x200.jpg)
![Enes Erul MD(@ErulEnes) 's Twitter Profile Photo Enes Erul MD(@ErulEnes) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/1746654972278673412/MjMSHqJK_200x200.jpg)
🔬 Trastuzumab deruxtecan shows promise in HER2-mutant solid tumors, with a 29.4% objective response rate in heavily treated patients. Safety profile manageable, supporting further investigation across tumor types. #CancerResearch #HER2Mutations OncoAlert
![Enes Erul MD (@ErulEnes) on Twitter photo 2024-05-07 13:49:30 🔬 Trastuzumab deruxtecan shows promise in HER2-mutant solid tumors, with a 29.4% objective response rate in heavily treated patients. Safety profile manageable, supporting further investigation across tumor types. #CancerResearch #HER2Mutations @OncoAlert 🔬 Trastuzumab deruxtecan shows promise in HER2-mutant solid tumors, with a 29.4% objective response rate in heavily treated patients. Safety profile manageable, supporting further investigation across tumor types. #CancerResearch #HER2Mutations @OncoAlert](https://pbs.twimg.com/media/GM-w_67XgAAB1TU.jpg)
![Deniz Can Guven(@DenizCanGuven1) 's Twitter Profile Photo Deniz Can Guven(@DenizCanGuven1) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/1233827983816785920/sIKpuig3_200x200.jpg)
Out in eClinicalMedicine – The Lancet Discovery Science
An SR-MA of psychological outcomes in rare cancers 🦓🦓
☑️Over 50.000 patients
☑️Increased depression (RR = 2.61) and anxiety (RR = 2.66)
⚠️⚠️Higher rates of suicide and PTSD
Call for immediate action ‼️‼️
Kudos to all authors Valerie Yang
#OncoAlert
![Deniz Can Guven (@DenizCanGuven1) on Twitter photo 2024-05-07 04:06:27 Out in @eClinicalMed An SR-MA of psychological outcomes in rare cancers 🦓🦓 ☑️Over 50.000 patients ☑️Increased depression (RR = 2.61) and anxiety (RR = 2.66) ⚠️⚠️Higher rates of suicide and PTSD Call for immediate action ‼️‼️ Kudos to all authors @val_yang #OncoAlert Out in @eClinicalMed An SR-MA of psychological outcomes in rare cancers 🦓🦓 ☑️Over 50.000 patients ☑️Increased depression (RR = 2.61) and anxiety (RR = 2.66) ⚠️⚠️Higher rates of suicide and PTSD Call for immediate action ‼️‼️ Kudos to all authors @val_yang #OncoAlert](https://pbs.twimg.com/media/GM8ofGfWsAAs8pA.png)
![Alper Topal, MD(@dralpertopal) 's Twitter Profile Photo Alper Topal, MD(@dralpertopal) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/1717757499418333184/goqTDEyK_200x200.jpg)
![Emre Yekedüz(@yekeduz_emre) 's Twitter Profile Photo Emre Yekedüz(@yekeduz_emre) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/1751043392782614528/6vRu40Fo_200x200.jpg)
![Deniz Can Guven(@DenizCanGuven1) 's Twitter Profile Photo Deniz Can Guven(@DenizCanGuven1) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/1233827983816785920/sIKpuig3_200x200.jpg)
![Erman Akkus(@Erman_Akkus) 's Twitter Profile Photo Erman Akkus(@Erman_Akkus) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/1451492444344922116/4k5Kxdfd_200x200.jpg)
![Emre Yekedüz(@yekeduz_emre) 's Twitter Profile Photo Emre Yekedüz(@yekeduz_emre) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/1751043392782614528/6vRu40Fo_200x200.jpg)
![Dra. María Natalia Gandur Quiroga(@nataliagandur) 's Twitter Profile Photo Dra. María Natalia Gandur Quiroga(@nataliagandur) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/1541027400447844352/9k4tpmnY_200x200.jpg)
3️⃣2️⃣1️⃣⏰️🔝Counting down the days! Just one month left until #ASCO24 🌍
Team OncoAlert is geared up and ready to go! 🚨
🌟 Featuring global team:
Gil Morgan, MD 🇺🇸
Alizée Camps - - Maléa 🇫🇷
Marta Perachino 🇮🇹
Kathrin Heinrich 🇩🇪
Biagio Ricciuti, MD PhD 🇺🇸
Deniz Can Guven 🇹🇷
Emre Yekedüz
![Tugce Telli(@ecguTelli) 's Twitter Profile Photo Tugce Telli(@ecguTelli) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/1573991847046807552/JALkxQUw_200x200.jpg)
![Deniz Can Guven(@DenizCanGuven1) 's Twitter Profile Photo Deniz Can Guven(@DenizCanGuven1) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/1233827983816785920/sIKpuig3_200x200.jpg)
Really interesting article by Niklas Klümper in EJC 🤓🤓
Post-hoc analyses from the IMvigor211 and IMmotion151 💉💉
A simple and cheap predictor of IO efficacy >Blood sodium levels 🧂🧂
Could be very practical and beneficial for the patients 🤞🤞
A great discussion on the
![Deniz Can Guven (@DenizCanGuven1) on Twitter photo 2024-05-03 09:21:39 Really interesting article by @niklas_kluemper in EJC 🤓🤓 Post-hoc analyses from the IMvigor211 and IMmotion151 💉💉 A simple and cheap predictor of IO efficacy >Blood sodium levels 🧂🧂 Could be very practical and beneficial for the patients 🤞🤞 A great discussion on the Really interesting article by @niklas_kluemper in EJC 🤓🤓 Post-hoc analyses from the IMvigor211 and IMmotion151 💉💉 A simple and cheap predictor of IO efficacy >Blood sodium levels 🧂🧂 Could be very practical and beneficial for the patients 🤞🤞 A great discussion on the](https://pbs.twimg.com/media/GMpNVUiWcAAsWlZ.jpg)
![Deniz Can Guven(@DenizCanGuven1) 's Twitter Profile Photo Deniz Can Guven(@DenizCanGuven1) 's Twitter Profile Photo](https://pbs.twimg.com/profile_images/1233827983816785920/sIKpuig3_200x200.jpg)
Best way to stay updated in the #Oncotwitter 💯💯
Great weekly summaries by the Mr. OncoAlert himself 🤓🤓 Gil Morgan, MD
Happy to see some friends too 🇹🇷🇹🇷 Emre Yekedüz Erman Akkus
Dra. María Natalia Gandur Quiroga Alizée Camps - - Maléa Marta Perachino Kathrin Heinrich Hidehito HORINOUCHI Dr. Iván R. González